95 results about "O-methyltransferase" patented technology

Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.

A method of treating Parkinson's disease by administering the racemic mixture of D,L-DOPA in combination with both peripheral amino acid decarboxylase and catechol, O-methyltransferase (COMT) inhibitors in pharmaceutically acceptable salts forms and effective doses for the treatment of Parkinson's disease. Alternatively, D-DOPA is administered in combination with both peripheral amino acid decarboxylase and catechol, O-methyltransferase (COMT) inhibitors in pharmaceutically acceptable salts forms and effective doses for the treatment of Parkinson's disease.

The present invention provides a method for producing an alkaloid, for example, reticuline, comprising providing dopamine as a substrate for a series of actions of monoamine oxidase, norcoclaurine-6-O-methyltransferase, coclaurine-N-methyltransferase and 3′-hydroxy-N-methylcoclaurine-4′-O-methyltransferase.

The present invention provides a sweet sorghum plant characterized by altered lignin content and/or altered lignin composition compared to a wild plant and this is achieved by manipulating the expression of caffeoylCoA-O-methyltransferae (CCoAOMT) in particular and optionally caffeic acid-O-methyltranferase (COMT) in sweet sorghum by incorporation of a construct comprising an isolated DNA sequence represented by SEQ ID NO 2 and optionally SEQ ID NO 1.

Methods for transforming forage legumes or woody plants with a DNA construct comprising at least one open reading frame encoding for a caffeoyl CoA 3-O-methyltransferase enzyme or a Medicago sativa caffeic acid 3-O-methyltransferase enzyme or a fragment thereof in either a sense or antisense orientation under a lignification-associated tissue specific promoter have been found, resulting in the down-regulation of the corresponding homologous gene either through antisense inhibition or sense suppression, as well as reduced lignin content and modified lignin composition in the transgenic plants. The expression of the caffeoyl CoA 3-O-methyltransferase transgene produces an increased syringyl lignin to guaiacyl lignin ratio in the transformed plant, and greatly improved forage digestibility.

Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express a mutant AROM polypeptide and/or mutant catechol-O-methyltransferase polypeptide alone or in combination with one or more vanillin biosynthetic enzymes or UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce vanillin or vanillin beta-D-glucoside.

There is disclosed a methylated intermediate which may be demethylated to provide an inhibitor of catechol-O-methyltransferase useful in the treatment of Parkinson's disease. Also disclosed are methods of making and using said intermediate.

The invention belongs to the technical field of medicines and relates to engineering bacteria for mainly generating gentamicin C1a and a constructing method of the engineering bacteria. 6'-C-O-methyltransferase gntK in micromonospora echinospora of gentamicin generated bacteria is damaged by using a gene blocking technology, so that the synthesis of gentamicin C1, C2 and C2a is blocked and gentamicin C1a and small part of gentamicin C2b are mainly generated. The contents of the C1A, the C2, the C2a and C1 in an original strain are 6.5 percent, 45.3 percent, 20.1 percent and 27.1 percent respectively; and the contents of the C1a and the C2b in a blocked strain are 94.0 percent and 6.0 percent respectively. According to the constructing method, the gntK gene in the micromonospora echinospora is damaged by a method of deleting in the architecture to inactivate, including the construction of gntK gene blocking plasmid, conversion of the blocking plasmid into the micromonospora echinospora, screening of a double-exchange strain and analysis of a fermentation product. The engineering bacteria constructed by the constructing method provided by the invention have no resistant marker; and through continuous passage, the yield of the gentamicin C1a is very stable.

The invention provides a specific probe substrate of catechol-O-methyltransgerase and application thereof. The specific probe substrate is a 7,8-dihydroxycoumarin compound and can be used for determination of activity of COMT enzyme in mammalian tissue and cells from different sources. The determination comprises the following concrete steps: selecting a coumarin compound having hydroxyl groups at positions 7 and 8 as a highly specific probe substrate; carrying out a COMT catalyzed reaction of the specific probe substrate in virtue of a COMT in-vitro incubation system; and determining the activity of COMT enzyme in each biological sample and each cell through quantitative detection of a product generation amount per unit time. The specific probe substrate can be used for quantitative evaluation of the activity of COMT enzyme in biological samples of different species and from different individual sources and quantitative determination of the activity of COMT enzyme in different-source-derived animal tissue cell culture fluids and prepared cell products, so assessment of capability of the important drug metablic enzyme COMT in disposition of drugs can be realized.

The invention provides an o-methyltransferase with a wide range of substrates, and can be applied to oxygen methyl transfer in a biosynthesis process of an organic compound. An experiment proves the catalytic activity of the o-methyltransferase, and shows that the o-methyltransferase can be applied to a plurality of substrates. The invention further provides a synthesis method for a hydroquinone lactone compound. The hydroquinone lactone compound is obtained by transforming an o-methyltransferase gene and a hydroquinone lactone synthetic gene into yeast cells, carrying out fermentation cultivation and extracting a product.

The invention relates to a medicine composition of myricetrin or/and myricetin aglycone thereof and levodopa or of levodopa and carbidopa and an application of myricetrin or/and myricetin aglycone thereof as a synergist in preparation of a medicine used for treating Parkinson. In vitro activity determination finds that IC50 of myricetrin and myricetin inhibiting catechol-O-methyltransferase (COMT) can be a micromole-nanomole scale. Rat overall pharmacokinetic study finds that blood concentration of levodopa can be increased after myricetrin and myricetin aglycone thereof and levodopa are used jointly; and myricetrin and myricetin aglycone thereof are high in safety, no obvious toxicity is produced to main visceral organ cells of a human body, and no active intermediate is produced by virtue of metabolism activation and further no damage done to organs such as liver and kidney is initiated, so that the myricetrin and myricetin aglycone thereof have a good application prospect in adjuvant therapy of Parkinson.

The invention provides a mass spectrum detection method for interaction between an active protein and a small molecule. According to the method, in-vivo covalent chemical labeling is performed on a protein while the active state is maintained; and the site and the intensity of the interaction between a small molecule and the protein are judged through the difference in the labeling efficiency before and after the interaction between the specific amino acid position on the protein and the small molecule. According to the present invention, with the mass spectrum detection method, the protein inhibitor candidate small molecule can be subjected to high-throughput screening, and the potential protein target of the specific small molecule can be subjected to large-scale identification analysis;and through the large-scale identification analysis of the Catechol-O-methyltransferase (COMT)-small molecule interaction and the ATP-binding protein in the complex system biological system, the method has accuracy and high efficiency.

The invention provides O-methyltransferase participating in citrus peel flavone synthesis and a coding gene and application thereof. The expression level of CitOMT1 is positively correlated with the accumulation of polymethoxylated flavones in a fruit development process of Citrus reticulata cv. Suavissima; in vitro enzyme activity assays indicate that the O-methyltransferase can be applied to catalyze specific site methylation of flavones, in particular to catalyze quercetin to produce quercetin 3',4' dimethyl ester, catalyze luteolin to produce chrysoeriol, catalyze eriodictyol to produce hesperidin and homoeriodictyol, catalyze baicalein to produce oroxylin A, and catalyze 7,8-dihydroxyflavone to produce 7-hydroxy-8-methoxy flavone. The enzyme activity assays have simple reaction conditions, do not require additional metal ions, and have high application value and research prospects.

The present invention is directed to a composition including N-Coumaroyldopamine and a catechol-o-methyltransferase (COMT) inhibitor for promoting weight loss in a user.

It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of trans-thyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate.

A biosynthetic method of making pterostilbene including expressing a 4- coumaratexoenzyme A ligase (4CL) in a cellular system, expressing a stilbene synthase (STS) in the cellular system, expressing a resveratrol O-methyltransferase (ROMT) in the cellular system, feeding p-coumaric acid to the cellular system, growing the cellular system in a medium, and producing pterostilbene.

The present invention discloses a method of eliciting an immune response and a method of vaccination comprising administration of a mutated flavivirus. The mutated flavivirus comprises at least one mutation in a nucleic acid sequence encoding for the non-structural protein 5 of the flavivirus sequence resulting in inactivation of the 2′O-methyltransferase.

The invention provides a specific fluorescent probe for COMT and application thereof. A specific probe substrate provided by the invention is 3-benzothiazole-7,8-dihydroxycoumarin (3-BTD); the substrate can be specifically catalyzed by COMT to produce an 8-methoxy product and presents a fluorescence signal at a position of 520 nm; and the activity of COMT can be quantitatively determined by detecting changes of fluorescence intensity. The probe is applicable to quantitative assessment of the activity of COMT in biological samples from different sources, in-vitro rapid screening of inhibitors for COMT and evaluation of the inhibitory capability of the inhibitors. A method provided by the invention can be used for quantitative assessment of the actual activity of COMT in a variety of in-vitro biological samples and realizes rapid screening of inhibitors and quantitative assessment of the inhibitory capability of the inhibitors; the method is also applicable to evaluation of the catalytic activity of COMT of different species and COMT mutants with different amino acid sequences, so the method can assess the capability of COMT in metabolization of catechol drugs; and the method has the advantages of high sensitivity, high accuracy, good environment interference resisting capability, convenience in high-flux detection and inhibitor screening, etc.